Clinical Trial Update: Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Avutometinib (VS-6766) with Sotorasib, with or without Defactinib, in KRAS G12C NSCLC; currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)
• sotorasib (sotorasib)

Snippet

Sponsor: Verastem, Inc. | Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING